Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

Key Terms

models-as-a service technical

Models-as-a-service are cloud-based offerings that let businesses use prebuilt predictive or decision-making models on demand, like renting a ready-made tool instead of building it from scratch. For investors, they matter because they lower the cost and time to add advanced analytics or automation, but also create ongoing vendor reliance, variable costs, and potential data or regulatory risks that can affect a company’s competitiveness and margins.

in-silico technical

Computer-based experiments, simulations or models used to study biological, chemical or pharmacological processes instead of—or before—doing physical lab work. Think of it as using a detailed flight simulator to test new drug ideas or disease models: it can speed research, cut costs and help identify the most promising candidates, which matters to investors because it can reduce development time, lower risk and improve the likelihood of successful outcomes.

multi-objective optimization technical

A method for finding the best trade-offs when decisions must satisfy several competing goals at once, such as maximizing returns while minimizing risk or cost. Think of choosing a car by balancing price, fuel efficiency and safety: no single option is perfect, so you pick the mix that fits priorities. Investors care because it helps design portfolios, projects or business plans that balance competing objectives and reveal the cost of improving one goal at the expense of another.

New AI Models-as-a-Service offering to integrate in-silico design with experimental data to continuously improve predictive power and accelerate scientific innovation

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY) today announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in‑silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and refine candidate molecules with increasing confidence.

Across life sciences and materials research, the application of artificial intelligence and machine learning is rapidly shifting discovery from trial-and-error experimentation toward predictive, data driven design. While powerful algorithms and models continue to emerge, their real‑world impact is limited without tight integration with high‑quality experimental data and the workflows scientists already use. The Signals Xynthetica offering is intended to address this gap by embedding models directly into the scientific context, connecting AI predictions with real wet-lab outcomes to drive continuous learning and improvement.

The Signals Xynthetica platform will support a wide range of in-silico design approaches, including de novo generation, property prediction, and multi-objective optimization. Delivered as an AI MaaS offering, it enables organizations to access, govern, and apply predictive models without building or maintaining a complex AI infrastructure. Models can be used consistently across projects, refreshed as new data emerges, and evaluated transparently alongside experimental results.

“AI has enormous potential to transform how molecules and materials are designed, but that potential is only realized when models are connected to real scientific workflows and data,” said Kevin Willoe, president of Revvity Signals Software. “The Signals Xynthetica platform is about operationalizing predictive science that brings in-silico design and experimental validation together in a continuous loop, accelerating discovery across industries.”

The Signals Xynthetica offering is expected to become a cornerstone of Revvity’s broader vision for AI-augmented discovery, enabling customers to harness predictive power at scale while maintaining strong governance, data stewardship, and scientific rigor. Pre-registration for customers is underway with early access programs available in 1H 2026.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251216271078/en/

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Media Relations:

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Source: Revvity